<DOC>
	<DOCNO>NCT01426802</DOCNO>
	<brief_summary>The study design demonstrate short term efficacy safety vildagliptin 50 mg bid patient Type 2 Diabetes Mellitus inadequately control Metformin .</brief_summary>
	<brief_title>Vildagliptin 50 mg Twice Daily Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients sign inform consent HbA1c range &gt; 7 ≤10.5 % Visit 1 Ability comply study requirement Pregnant lactate woman Serious cardiovascular disorder Liver/renal disease dysfunction Antidiabetic metformin , thiazolidine , αGI insulin Laboratories value abnormality define protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>metformin</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>T2DM</keyword>
</DOC>